Clinical Trials Logo

22q Telomere Deletion Syndrome clinical trials

View clinical trials related to 22q Telomere Deletion Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT02299245 Active, not recruiting - Telomere Shortening Clinical Trials

Rosuvastatin Effect on Telomere-telomerase System in ACS

Start date: October 2014
Phase: Phase 4
Study type: Interventional

Coronary heart disease (CHD) is one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. The mean telomere length and telomerase activity serve as markers for the biological age at the cellular level, with shorter telomeres and lower telomerase activity defining the increased biological age. Telomere length and telomerase activity, therefore, correlates with the risk of CHD and atherosclerosis. A present study states that the treatment with a statin is associated with a reduction in the number of clinical events but only in individuals with increased risk based on their telomere length. This suggests a positive relationship of telomere and telomerase system with the treatment with statins in CHD patients.